Second Dose of Kisspeptin Safely Optimises Oocyte Maturation in Women Undergoing IVF: Presented at ESHRE

By Jenny Powers

GENEVA -- July 6, 2017 -- A second dose of kisspeptin safely optimises oocyte maturation in women undergoing in in vitro fertilisation (IVF) treatment, without increasing the risk of ovarian hyperstimulation syndrome (OHSS), according to a study presented here on July 4 at the 33rd Annual Meeting of the European Society for Human Reproduction and Embryology (ESHRE).

An oocyte yield ≥60% was achieved by 45.2% of women receiving a single dose of kisspeptin, compared with 71.0% of women receiving 2 doses of kisspeptin spaced 10 hours apart (P = .042).

“We have previously reported that a single dose of kisspeptin results in an LH [luteinizing hormone] surge lasting approximately 12 to 14 hours, which safely triggered oocyte maturation in women at high risk of OHSS,” noted Ali Abbara, Imperial College in London, London, United Kingdom.

All of the women enrolled in the trial underwent IVF and received a subcutaneous injection of kisspeptin 9.6 nmol/kg 36 hours prior to oocyte retrieval. Women were then randomised 1:1 to receive either a second dose of kisspeptin (n = 31) or saline (n = 31) 10 hours after the first kisspeptin injection.

The primary outcome of the study was the proportion of patients achieving a percentage of mature oocytes retrieved from follicles ≥14mm of ≥60%.

Following the second dose of kisspeptin additional secretion of LH was observed at 4 and 10 hours after injection compared with saline (P < .0001).

The LH-response following the second kisspeptin dose was variable and seemed to be determined by the LH-response following the first kisspeptin injection. The variable LH-response to the second dose of kisspeptin meant that the frequency of ovarian over-response and OHSS was not increased, according to Dr. Abbara.

“Our next step is to conduct a larger randomised trial that directly compares kisspeptin to more established triggers of oocyte maturation,” he said.

[Presentation title: A Second Dose of Kisspeptin Safely Optimizes Oocyte Maturation in Women Undergoing in IVF Treatment: a Phase 2 Randomized Controlled Trial. Abstract O-117]

To read more Conference Dispatch articles, click here.